BLADDER CANCER: Clinical Updates. Stable patient function, health reported with N-803 plus BCG in NMIBC.

COMBINATION drug therapy; NON-muscle invasive bladder cancer; HEALTH status indicators; BCG vaccines; CLINICAL trials; INTERLEUKINS

The article reveals the stable two-year physical function and global health measures with N-803 plus Bacille Calmette-Guerin (BCG) in patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and papillary disease treated with interleukin-15 superagonist N-803 in combination with BCG, according to patient-reported outcome data from the phase two/three QUILT 3.032 study. The study showed complete response among the patients and longer cystectomy avoidance rate.